BofA says Elevidys risk-reward favorable despite Sarepta report of patient death

After Sarepta (SRPT) reported the death of a Duchenne muscular dystrophy patient following treatment with Elevidys after suffering acute liver failure, BofA notes that acute liver failure is a known side effect of AAV-mediated gene therapies and is already included in the Elevidys label, but management highlighted they have dosed over 800 patients to date without any reports of ALF. The firm thinks the risk-benefit profile of Elevidys remains favorable as this seems to be an isolated incident given the large number of patients dosed to-date without any safety signals, but adds that it will continue to monitor the situation. BofA thinks the news could result in weakness in the stock today, which it would view as “a particularly attractive entry point,” and it adds that Sarepta remains a top 2025 pick with a Buy rating and $210 price target